Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: desvenlafaxine succinate

« Back to Dashboard

Desvenlafaxine succinate is the generic ingredient in one branded drug marketed by Wyeth Pharms Inc and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for desvenlafaxine succinate. Six suppliers are listed for this compound.

Summary for Generic Name: desvenlafaxine succinate

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list12
Suppliers: see list6

Clinical Trials for: desvenlafaxine succinate

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women
Status: Recruiting Condition: Major Depressive Disorder; Menopausal Staging and Vasomotor Symptoms (for Females)

Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder
Status: Completed Condition: Major Depressive Disorder

Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females
Status: Completed Condition: Healthy

Desvenlafaxine in Opioid-Dependent Patients
Status: Recruiting Condition: Depression; Opioid Dependence

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Status: Completed Condition: Major Depressive Disorder

Desvenlafaxine Monotherapy in Dysthymia
Status: Completed Condition: Dysthymic Disorder

Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression
Status: Not yet recruiting Condition: Vascular Depression

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
Status: Completed Condition: Pharmacokinetics; Cytochrome P-450 CYP2D6; CYP3A4 Protein, Human

Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Status: Recruiting Condition: Dysthymic Disorder; Dysthymia; Chronic Depressive Disorder

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
Status: Completed Condition: Major Depressive Disorder

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes<disabled><disabled>
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Aug 20, 2014RXNo<disabled><disabled>
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes6,673,838<disabled>Y<disabled>
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992Feb 29, 2008RXYes8,269,040<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc